Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia

A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis

(2019) Maya R. Jacobson et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial

(2018) Philip McGuire et al.   AMERICAN JOURNAL OF PSYCHIATRY

The endocannabinoid system in mental disorders: Evidence from human brain studies

(2018) Inés Ibarra-Lecue et al.   BIOCHEMICAL PHARMACOLOGY

Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016

(2018) Fiona J Charlson et al.   SCHIZOPHRENIA BULLETIN

Differential regulation of the TLR4 signalling pathway in post-mortem prefrontal cortex and cerebellum in chronic schizophrenia: Relationship with SP transcription factors

(2017) Karina S. MacDowell et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia

(2016) David W. Volk et al.   BIOLOGICAL PSYCHIATRY

Reduced Brain Cannabinoid Receptor Availability in Schizophrenia

(2016) Mohini Ranganathan et al.   BIOLOGICAL PSYCHIATRY

Positron Emission Tomography Studies on Cannabinoid Receptor Type 1 in Schizophrenia

(2016) Yoan Mihov   BIOLOGICAL PSYCHIATRY

An Introduction to the Endogenous Cannabinoid System

(2016) Hui-Chen Lu et al.   BIOLOGICAL PSYCHIATRY

Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia

(2016) Marc Fakhoury   MOLECULAR NEUROBIOLOGY

Distinct neuronal activation patterns are associated with PCP-induced social withdrawal and its reversal by the endocannabinoid-enhancing drug URB597

(2016) Julien Matricon et al.   NEUROSCIENCE RESEARCH

Biased Agonism of Three Different Cannabinoid Receptor Agonists in Mouse Brain Cortex

(2016) Rebeca Diez-Alarcia et al.   Frontiers in Pharmacology

Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)

(2015) Matthew W. Elmes et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The endocannabinoid system is altered in the post-mortem prefrontal cortex of alcoholic subjects

(2014) Amaia M. Erdozain et al.   ADDICTION BIOLOGY

Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: Effect of antidepressant treatment

(2014) Carolina Muguruza et al.   NEUROPHARMACOLOGY

Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia

(2014) David W. Volk et al.   SCHIZOPHRENIA RESEARCH

Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia

(2013) Jenny Ceccarini et al.   NEUROIMAGE

Endocannabinoid metabolism in the prefrontal cortex in schizophrenia

(2013) David W. Volk et al.   SCHIZOPHRENIA RESEARCH

Quantification of endocannabinoids in postmortem brain of schizophrenic subjects

(2013) Carolina Muguruza et al.   SCHIZOPHRENIA RESEARCH

The Endocannabinoid System and the Brain

(2012) Raphael Mechoulam et al.   Annual Review of Psychology

A Systematic Review and Meta-Analysis of Recovery in Schizophrenia

(2012) E. Jaaskelainen et al.   SCHIZOPHRENIA BULLETIN

Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia

(2012) Kimberly J. Jenko et al.   SCHIZOPHRENIA RESEARCH

Endocannabinoid system dysfunction in mood and related disorders

(2011) C. H. Ashton et al.   ACTA PSYCHIATRICA SCANDINAVICA

Paranoid Schizophrenia is Characterized by Increased CB1 Receptor Binding in the Dorsolateral Prefrontal Cortex

(2011) Victoria S Dalton et al.   NEUROPSYCHOPHARMACOLOGY

Alterations in Metabotropic Glutamate Receptor 1α and Regulator of G Protein Signaling 4 in the Prefrontal Cortex in Schizophrenia

(2010) David W. Volk et al.   AMERICAN JOURNAL OF PSYCHIATRY

Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors

(2010) Philip G. Strange   BRITISH JOURNAL OF PHARMACOLOGY

Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR

(2010) Dean F. Wong et al.   NEUROIMAGE

Cannabinoid CB1 Receptor Immunoreactivity in the Prefrontal Cortex: Comparison of Schizophrenia and Major Depressive Disorder

(2010) Stephen M Eggan et al.   NEUROPSYCHOPHARMACOLOGY

Brain Cannabinoid CB2 Receptor in Schizophrenia

(2009) Hiroki Ishiguro et al.   BIOLOGICAL PSYCHIATRY

Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats

(2009) Alexandre Seillier et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment

(2009) Leyre Urigüen et al.   PSYCHOPHARMACOLOGY

Reduced Cortical Cannabinoid 1 Receptor Messenger RNA and Protein Expression in Schizophrenia

(2008) Stephen M. Eggan et al.   ARCHIVES OF GENERAL PSYCHIATRY